EPI-321 awarded US orphan drug designation for facioscapulohumeral muscular dystrophy
Nov. 16, 2023
Epic Bio (Epicrispr Biotechnologies Inc.) has announced that EPI-321 has been awarded U.S. orphan drug designation for the treatment of facioscapulohumeral muscular dystrophy (FSHD).